
|Videos|March 15, 2017
High Cost Impacts PCSK9 Inhibitor Access
Author(s)Lauren Santye, Assistant Editor
Mark Tesell, PharmD, BCPS, discusses how the high cost of PCSK9 inhibitors effected uptake of the cholesterol-lowering drug.
Advertisement
Mark Tesell, PharmD, BCPS, discusses how the high cost of PCSK9 inhibitors effected uptake of the cholesterol-lowering drug.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
2
Up to 5 Cups of Coffee Daily Safe—and Benficial—for Most Adults
3
Pharmacist Outreach Doubles SGLT2 Inhibitor Uptake in CKD
4
mRNA COVID-19 Booster Outperforms Protein-Based Shot on Antibodies, But Both Cut Infections Over 12 Months
5





































































































